MoneyWorks4Me

Cadila Healthcare informs about press release

18 Sep 2021 Evaluate

Cadila Healthcare has informed that it enclosed Press release dated September 18, 2021 titled 'Zydus Cadila receives final approval from USFDA for Vortioxetine Tablets’.

The above information is a part of company’s filings submitted to BSE.

Zydus Lifesciences Share Price

1117.20 12.20 (1.10%)
20-Aug-2026 11:51 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1896.30
Dr. Reddys Labs. 1175.35
Cipla 1433.70
Lupin 2218.65
Zydus Lifesciences 1117.20
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: